Article
作者: Pozo, Juan del ; O’Reilly, Marc ; Ryan, Michael C. ; Han, Yongxin ; Burgess, Samantha A. ; Hamlett, Christopher C. F. ; Ueno, Hiroyuki ; Shibata, Kazuaki ; Schoepf, Patrick ; De Jesus Silva, Jordan ; Sagara, Takeshi ; Rath, Barbara ; Terasaka, Miki ; Day, Philip J. ; Duggal, Ruchia ; Abe, Naomi ; Akemoto, Kei ; Komori, Toshiharu ; Munsell, Erik V. ; Kondo, Hitomi ; Yamamoto, Tomohiro ; Wakayama, Kentaro ; Chessari, Gianni ; Mayhood, Todd W. ; Xu, Zangwei ; Mizuarai, Shinji ; Lacey, Brian M. ; Agnew, Christopher ; Rees, David C. ; Sakamoto, Toshihiro ; Jiang, Yuan ; Giambasu, George M. ; Chai, Xiaomei ; Solban, Nicolas ; Sugimoto, Tetsuya ; Kida, Taiki ; Hennessy, Elisabeth ; Asakura, Hiroki ; Song, Xuelei Sherry ; Miura, Risako ; Bennett, David Jonathan ; Twigg, David G. ; Stoeck, Alexander
Abstract:Current KRASG12C inhibitors mainly target the inactive GDP-bound state, but clinical efficacy is limited, and resistance mechanisms have been identified. We disclose novel covalent inhibitors that selectively target the active GTP-bound KRASG12C. Starting from a high-throughput screen, we identified a keto-indolizine scaffold featuring an aniline-derived acrylamide warhead that covalently binds Cys12 in the switch-II pocket of active KRASG12C. X-ray crystallography revealed key interactions of acrylamide with GMPPCP′s γ-phosphate, stabilizing the GTP state. We present medicinal chemistry efforts leading to the discovery of compound 17, which shows favorable oral bioavailability in preclinical species, exhibiting prolonged disruption of the KRAS-cRAF interaction and downstream ERK phosphorylation in vivo. In a KRASG12C-driven pancreatic cancer xenograft model (MIA PaCa-2), orally administered compound 17 achieved complete tumor regression for up to 45 days with good tolerability. This study establishes a novel class of KRASG12C inhibitors targeting the active GTP-bound state, which may have the potential to overcome some resistance mechanisms.